Source:http://linkedlifedata.com/resource/pubmed/id/12802917
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2003-6-13
|
| pubmed:abstractText |
The aim of this study is to verify the feasibility and the clinical activity of a new CHOP-like schedule (ACOD) with a fractionated days 1 and 8 administration in elderly patients. This regimen was chosen in the attempt to allow a sufficient dose intensity (DI) of each drug with better compliance. Fifty-two patients, (74 years, median age), with diffuse large B cell non-Hodgkin's lymphoma were retrospectively evaluated. Patients received ADM 25 mg/sqm, CTX 500 mg/sqm, VCR 1.2 mg/sqm (max 2 mg intravenously) days 1 and 8 and PDN 50 mg orally, days 1-8. Results showed that 54% of patients reached a complete remission, 21% a partial remission with an overall response rate of 75%. Two-thirds of the patients received at least 70% of the planned dose of cyclophosphamide and doxorubicin and 50% of vincristine and prednisone. The median duration of follow up was 12.6 months (range 0.7-61.4). The estimated median OS was 15.2 months (95%CI = [11.6, not estimable]); the estimated median PFS was 5.7 months (95%CI = [5.12, not estimable]). After 2 years, the proportion of patients alive was 47% (95%CI = 34-64%) and the proportion of patients free from progression was 39% (95%CI = 27-57%). Grade 3-4 leukopenia was observed in 61% of patients with 11% of febrile neutropenia. In conclusion, the ACOD chemotherapy regimen seems safe and feasible in elderly patients. This schedule allowed a sufficient DI of chemotherapic agents with clinical results very similar to those recorded with the standard CHOP regimen in young adults.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1042-8194
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
44
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
801-6
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12802917-Aged,
pubmed-meshheading:12802917-Aged, 80 and over,
pubmed-meshheading:12802917-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12802917-Cyclophosphamide,
pubmed-meshheading:12802917-Doxorubicin,
pubmed-meshheading:12802917-Drug Evaluation,
pubmed-meshheading:12802917-Female,
pubmed-meshheading:12802917-Humans,
pubmed-meshheading:12802917-Leukopenia,
pubmed-meshheading:12802917-Lymphoma, B-Cell,
pubmed-meshheading:12802917-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:12802917-Lymphoma, Non-Hodgkin,
pubmed-meshheading:12802917-Male,
pubmed-meshheading:12802917-Neutropenia,
pubmed-meshheading:12802917-Prednisone,
pubmed-meshheading:12802917-Remission Induction,
pubmed-meshheading:12802917-Retrospective Studies,
pubmed-meshheading:12802917-Survival Analysis,
pubmed-meshheading:12802917-Vincristine
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Division of Hematoncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
|
| pubmed:publicationType |
Journal Article
|